1st Sub.
H.B.
119
CONTROLLED SUBSTANCE DATABASE AMENDMENTS
house floor
Amendments
and the Utah attorney general, to:
of costs for in-house programming submitted by the pharmacy.
(a) investigate the causes of and risk factors for death and nonfatal complications of prescription
opiate use and misuse in Utah for chronic pain by utilizing the Utah Controlled Substance Database created in
Section
58-37-7.5
;
(b) study the risks, warning signs, and solutions to the risks associated with prescription opiate
medications for chronic pain, including risks and prevention of misuse and diversion of those medications;
and
}
(c) provide education to health care providers, patients, insurers, and the general public on the
appropriate management of chronic pain, including the effective use of medical treatment and quality care
guidelines that are scientifically based and peer reviewed
.
}
; and
(d) educate the public regarding:
(i) the purpose of the Controlled Substance Database established in Section 58-37-7.5; and
(ii) the requirement that a person's name and prescription information be recorded on the
database when the person fills a prescription for a schedule II, III, IV, or V controlled substance.
(3) The department shall report on the development and implementation of the program required in
Subsection (2) to the legislative Health and Human Services Interim Committee and the legislative Business
and Labor Interim Committee no later than the November interim meetings in 2007 and 2008. Each report
shall include:
(a) recommendations on:
(i) use of the Utah Controlled Substance Database created in Section
58-37-7.5
to identify and
prevent:
(A) misuse of opiates;
(B) inappropriate prescribing; and
(C) adverse outcomes of prescription opiate medications;
(ii) interventions to prevent the diversion of prescription opiate medications; and
(iii) medical treatment and quality care guidelines that are:
(A) scientifically based; and
(B) peer reviewed; and
(b) (i) a measure of results against expectations under the program as of the date of the report; and
(ii) an analysis of the application of the program, use of the appropriated funds, and the impact and
results of the use of the funds.
(4) The report provided under Subsection (3) for the 2008 interim shall also provide a final cumulative
analysis of the measurable effectiveness of the program implemented under this section.
7. Page
7, Line 205
:
205
58-37-7.8. Pilot program for
real time
}
real-time
reporting for controlled substance database
8. Page
8, Line 215
:
215
data from, the database by a pharmacy, a pharmaceutical facility, or a
physician
}
prescribing
practitioner
beginning on
9. Page
8, Line 225
:
225
(5) (a) All provisions and requirements of the
state-wide
}
statewide
database, described in
10. Page
9, Lines 246 through 249
:
246
(b) the progress made by the division in implementing the pilot program on a statewide
247
basis;
and
}
248
(c) the advisability of, and projected costs of, implementing the pilot program on a
249
statewide basis
.
}
; and
(d) the use of the database by prescribing practitioners.
11. Page
9, Line 260
:
260
(i)
12. Page
9, Lines 270 through 272
:
270
(i)
is secure
}
complies with the security standards described in 45 CFR Parts 160, 162,
and 164, Health Insurance Reform: Security Standards
{
; and
}
271
(ii) does not interfere with the proper functioning of the pharmacy's or pharmaceutical
272
facility's software or computer system
.
}
; and
(iii) in order to minimize changes in existing protocols, provides, to the extent practicable, for
the transmission of data in the same manner that pharmacies currently transmit information to
insurance companies.
(i) the pharmacy requests the reimbursement, in writing;
(ii) the pharmacy provides proof of the costs for the in-house programming to the division;
(iii) the pharmacy requests the reimbursement prior to a deadline established by the
division; and
(iv) except as provided in Subsection (11)(e), the division pays an equal reimbursement amount
to each pharmacy that complies with Subsections (11)(d)(i) through (iii).
(e) The division may reimburse a pharmacy described in Subsection (11)(d)(iv) for an amount
that is less than the reimbursement paid to other pharmacies described in Subsection (11)(d)(iv), if:
(i) the proof of costs for in-house programming provided by the pharmacy establishes a cost
less than the amount reimbursed to the other pharmacies; and
(ii) the amount reimbursed to the pharmacy is equal to the the amount established by the proof
13. Page
10, Lines 274 through 282
:
274
275
(1)
}
(a)
as an ongoing appropriation, subject to future budget constraints, $175,000 from
276
the General Fund for the fiscal year 2008-09, to the Division of Occupational and Professional
277
Licensing to maintain and operate the controlled substance database; and
278
(2)
}
(b)
$650,000 from the General Fund, for the fiscal year 2008-09 only, to the Division
279
of Occupational and Professional Licensing to
(i)
280
described in this bill
(ii) if any of the funds described in this Subsection (1)(b) are available after paying the
costs to implement and operate the pilot program under Subsection (1)(b)(i), reimburse a pharmacy for
the costs of in-house programming, in accordance with Subsection 58-37-7.8(11)(d)
281
(3)
}
(2)
The $650,000 appropriated from the General Fund, under Subsection (2), shall be
282
nonlapsing.
Page 1 of 4
hb0119s01.hfa.01.wpd
LRGC
TomVaughn
TomVaughn